-
Innovation Ranking
Innovation Ranking – Mesoblast Ltd
Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in phase III trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs),...
-
Product Insights
NewNet Present Value Model: Astellas Pharma Inc’s Bocidelpar Sulfate
Empower your strategies with our Net Present Value Model: Astellas Pharma Inc's Bocidelpar Sulfate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Mesoblast Ltd’s Rexlemestrocel-L
Empower your strategies with our Net Present Value Model: Mesoblast Ltd's Rexlemestrocel-L report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Mesoblast Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Mesoblast Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Hypoplastic Left Heart Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rexlemestrocel-L in Hypoplastic Left Heart Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Hypoplastic Left Heart Syndrome Drug Details: Rexlemestrocel-L is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rexlemestrocel-L in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Left Ventricular Dysfunction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rexlemestrocel-L in Left Ventricular Dysfunction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Left Ventricular Dysfunction Drug Details: Rexlemestrocel-L is under development...
-
Product Insights
Cartilage Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Cartilage Degeneration - Drugs In Development, 2023’, provides an overview of the Cartilage Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cartilage Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Congenital Heart Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Congenital Heart Disease - Drugs In Development, 2023’, provides an overview of the Congenital Heart Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Left Ventricular Dysfunction – Drugs In Development, 2023
Global Markets Direct’s, ‘Left Ventricular Dysfunction - Drugs In Development, 2023’, provides an overview of the Left Ventricular Dysfunction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...